We have previously characterized a cDNA that encodes a full length human UDP-GalNAc:polypeptide, N-acetylgalactosaminyltransferase (GalNAc-transferase) (J.A. Meurer et al., J. Biochem., 118, 568-574,1995). The present report describes the characterization of the corresponding human GalNAc-transferase gene and a related pseudogene. Two human genomic libraries, A and PI, were screened with probes derived from the human GalNActransferase nucleotide sequence, resulting in the isolation of four genomic clones. Southern blotting, PCR analysis, and sequencing revealed that three clones, A.HG-5, Pl.GALN-A, and Pl.GALN-B, contained overlapping genomic sequences that encompass over 55 kilobase pairs (kb) of genomic DNA and comprise a portion of the human GalNAc-transferase 5'-and 3'-untranslated regions and the entire coding region. The human GalNAc-transferase gene structure consists of at least 11 exons ranging in size from 99 to > 620 nucleotides which are separated by 10 introns ranging in size from 0.7 to ~ 12.5 kb. The fourth genomic clone, Pl-GALN-i/r, contained a ~ 2.4 kb sequence region which shares an overall 78.6% nucleotide identity with coding region exons 1 and 3 through 11 of the human GalNAc-transferase gene. However, a lack of intron sequences, as well as the presence of multiple nucleotide mutations, insertions, and deletions that disrupt the potential GalNAc-transferase reading frame, suggest that Pl.GALN-i/* contains a processed pseudogene. Screening of a human/rodent somatic cell hybrid panel with a Pl.GALN-«/f probe localized the GalNAc-transferase pseudogene to chromosome 3. Hence, the human genome contains at least two related GalNAc-transferase genes that are located on separate chromosomes.
Introduction
Glycosyltransferases are a large group of an estimated 100-200 intracellular, membrane-bound enzymes coordinately involved in the biosynthesis of a variety of carbohydrate structures (reviewed by Beyer and Hill, 1982; Kleene and Berger, 1993) . The majority of these enzymes catalyze the transfer of a specific monosaccharide from a nucleotide sugar donor to a defined acceptor, and the assembly of both N-and O-linked oligosaccharide structures on eukaryotic polypeptides is dependent on the presence and sequential action of specific glycosyltransferases (reviewed by Kornfeld and Kornfeld, 1985; Schachter and Brockhausen, 1992; Kleene and Berger, 1993) . Hence, considerable interest lies in the study of the regulation of these enzymes.
Over 25 different glycosyltransferase cDNAs have been isolated and characterized to date (Narimatsu, 1994; D'Agostaro et al., 1995; Hitoshi etal., 1995; Schulte and Stoffel, 1995; Strahan et al., 1995; Tan et al., 1995, and references therein; Yoshida et al., 1995) . In addition, the information obtained from several of the cloned cDNAs has been used to establish the organizations of the corresponding glycosyltransferase genes (Joziasse, 1992; Kleene and Berger, 1993; Schachter, 1994) .
UDP-GalNAc:polypeptide, /V-acetylgalactosaminyltransferase (GalNAc-transferase) (E.C. 2.4.1.41) initiates the biosynthesis of O-linked (mucin type) oligosaccharide structures on glycoproteins (Roseman, 1970) . Specifically, this enzyme transfers a single /V-acetylgalactosamine (GalNAc) from UDP-GalNAc to a serine or threonine residue on its polypeptide acceptors. GalNAc-transferase transcripts have been cloned from bovine intestine, bovine placenta, and human salivary gland cDNA sources (Homa et al., 1993; Tabak et al., 1993; Meurer et al., 1995) . The cDNAs for both the human and bovine GalNAc-transferases are predicted to encode type II, membrane-bound glycoproteins that share a domain structure common to all other cloned Golgi-resident glycosyltransferases. The human and bovine GalNAc-transferase polypeptides show a high degree of similarity, having deduced amino acid sequences that are ~ 99% identical (Meurer et al., 1995) . However, these predicted GalNAc-transferase polypeptides do not share substantial amino acid sequence identity with any other presently characterized glycosyltransferase.
0-Linked oligosaccharide structures on glycoproteins play important functional and structural roles in vivo (Schachter and Brockhausen, 1992; Brockhausen, 1993) . For example, a number of studies have demonstrated that O-glycans are involved in receptor-ligand interactions, viral and bacterial infectivity, gamete interaction, control of the immune system, and formation of cancer and cell differentiation antigens (see Schachter and Brockhausen, 1992; Brockhausen, 1993 , and references therein). These glycans reportedly also play an important structural role, by stabilizing the polypeptide to which they are attached, as well as by protecting the glycosylated protein from proteolytic degradation (Schachter and Brockhausen, 1992) .
In preparation for studies on the regulation of expression of the GalNAc-transferase enzyme and to gain further insight into its role in the control of O-glycosidic glycosyla-tion, we have isolated a functional human GalNAc-transferase gene and studied its structure and organization. In addition, we report the isolation and characterization of a related processed pseudogene with a distinctly different genetic locus.
Results

Isolation and characterization of human GalNActransferase genomic clones
The Southern blot analysis previously performed by Meurer et al. (1995) indicated that the human GalNActransferase gene may contain multiple exons, distributed over more than 40 kb of genomic DNA. With the goal of characterizing the human GalNAc-transferase gene, two human genomic libraries, A and PI, were screened for clones that contained sequences corresponding to the gene. Initially, one million recombinant plaques from a AFIX human placenta genomic library were probed with a [ 32 P]-labeled 263 bp cDNA fragment corresponding to the 5'-end coding region of human GalNAc-transferase cDNA (see Materials and methods). One hybridization-positive recombinant phage clone, A.HG-5, was isolated and subsequently characterized by Southern blotting using the same 263 bp cDNA probe. Two hybridization-positive A.HG-5 restriction fragments were isolated, a 1.4 kb EcoRl fragment and a 2.2 kb Hindlll fragment, which were subsequently subcloned and sequenced. The sequences obtained from these fragments revealed that clone A.HG-5 contains two GalNAc-transferase exons that share 100% identity with bp -31-139 and 140-314, respectively, of the human GalNAc-transferase cDNA (Meurer et al., 1995) . These exons are separated by an intron >9 kb in size, as determined by PCR analysis. These data suggest that clone A.HG-5 contains the first two coding region exons of the human GalNAc-transferase gene, separated by one intron (Figure 2) . Subsequent to the isolation of A.HG-5, it was realized that the cloning of the missing portions of the human GalNAc-transferase gene may be more effectively done using a vector library containing much larger DNA inserts (75-95 kb on average). Therefore, a Pl-bacteriophage human genomic library (reviewed by Sternberg, 1992) was screened using various human GalNAc-transferase genespecific PCR probes (outlined in Materials and methods and Figure 1 ). The first screening resulted in the isolation of one human PI clone, Pl.GALN-i/'. Southern blot analysis of the insert of Pl.GALN-i/> revealed that this clone contained a single EcoRl restriction fragment of 5.0 kb that hybridized with a full-length human GalNAc-transferase cDNA probe (Meurer et al., 1995) . Interestingly, more extensive Southern blot analyses, using DNA probes corresponding to either the 5'-or 3'-ends of the human GalNActransferase coding region, demonstrated that this 5.0 kb EcoRl restriction fragment potentially contained the complete GalNAc-transferase coding region (data not shown). Hence, the mapping data for the GalNAc-transferase-related sequence contained in the 5.0 kb £ccRI Pl.GALNip fragment was not consistent with that obtained for A. HG-5. Preliminary sequence analysis of the 5.0 kb £coRI fragment (obtained from subclone Pl.GALN-i/f/SK) revealed that it contains a related but distinctly different human GalNAc-transferase sequence. Analysis of portions of the putative coding region identified multiple termination codons in its predicted GalNAc-transferase reading frame. Hence, it appeared that the PI.GALN-i/>clone contained a GalNAc-transferase pseudogene. A more detailed analysis of Pl.GALN-t// is presented below.
To isolate a functional GalNAc-transferase gene, two further PI library screenings were performed, using the probing strategy outlined in the Materials and methods and in Figure 1 . These screenings resulted in the isolation of two PI clones, Pl.GALN-A and Pl.GALN-B, that were characterized by restriction digestion, Southern blotting, and direct sequencing. These analyses demonstrated that the inserts in Pl.GALN-A and Pl.GALN-B have restriction maps which partially overlap; each share two hybridization-positive EcoRI restriction fragments with clone A.HG-5 and four hybridization-positive EcoRI fragments with each other (data not shown). Pl.GALN-A was found to contain exon sequences corresponding to nucleotides -31 to 1299 of the human GalNAc-transferase cDNA, as well as over 30 kb of genomic sequence 5' of nucleotide -31 (Figure 2 ). Clone Pl.GALN-B contained genomic sequences corresponding to the coding and 3'-untranslated regions of the human GalNAc-transferase cDNA, as well as > 10 kb of genomic DNA 3' of cDNA nucleotide position 2154 (Meurer et al, 1995) . Therefore, Pl.GALN-A and Pl.GALN-B are overlapping clones which, together, contain the entire coding region of the human GalNActransferase gene as outlined in Figure 2 .
Genomic organization of the human GalNAc-transferase gene
The exon sequences and intron/exon boundaries of the human GalNAc-transferase gene were determined by directly sequencing Pl-GALN.A and Pl-GALN.B DNAs with oligonucleotide primers corresponding to portions of the human GalNAc-transferase cDNA (Meurer et al, 1995) . The resulting sequences were compared to the human GalNAc-transferase cDNA sequence to clearly define the locations of the GalNAc-transferase intron/exon boundaries. A total of 11 exons, separated by 10 introns, were identified, which account for all of the sequence contained in the human GalNAc-transferase cDNA (Meurer et al, 1995) . Table I lists a summary of the location and junction sequences for the intron/exon boundaries found in this analysis. All the introns have junction sequences that conform to the consensus sequences described by Mount (1982) ; they are bounded by 5' GT and 3' AG sequences and have intron acceptor sequences with a high C/T content near their 3' junctions (Table I) .
Using long range PCR analyses, it was established that the human GalNAc-transferase gene is distributed over 55 kb of genomic DNA and contains at least 11 exons ranging in size from 99 bp to > 620 bp, separated by 10 introns ranging in size from 0.7 to ~ 12.5 kb (Figure 2 ). Exons 1 through 10 average ~ 163 nucleotides in size, whereas exon 11 is greater than 620 bp and contains the known 3'-untranslated region sequence (the exact size of the 3'-untranslated region remains to be determined). The coding region is distributed over all 11 exons, and the GalNActransferase gene exon and cDNA sequences share 100% identity. (1) represents primer set 1 (E' and F'). and (2) represents primer set 2 (G' and H'). All primers are identified by letters and directional arrows.
Partial characterization of human GalNAc-transferase non-coding regions
Although clones Pl.GALN-A and Pl.GALN-B account for all of the previously published GalNAc-transferase cDNA sequence (Meurer et ai, 1995) , the extent of the 5'-and 3'-untranslated regions of the corresponding transcripts) is presently not known. A Northern blot analysis, performed by Homa et al. (1993) on various human tissues (including heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas), detected at least two human GalNAc-transferase transcripts of ~ 4.8 and 3.9 kb in all tissues tested. The human salivary gland GalNAc-transferase cDNA sequence reported by Meurer et al. (1995) is 2185 bp in length, which is ~ 2.6 and 1.7 kb shorter, respectively, than the two transcripts identified by Homa et al. (1993) . Thus, it is possible that significant portions of the human GalNAc-transferase non-coding regions remain to be determined. In an attempt to isolate the remaining GalNAc-transferase 5'-untranslated region, the 5' rapid amplification of cDNA ends (5'-RACE) PCR technique of Frohman et al. (1988) was performed, using human salivary gland cDNA as a template. This procedure produced amplified products which averaged ~ 150 bp in length (larger amplified products were not generated). The PCR products were subcloned and the DNAs from five purified clones were subsequently sequenced. The nucleotide sequence of the longest 5'-RACE clone, pCII/3, is 147 nucleotides in length and extends 123 bp upstream of the human GalNAc-transferase translation initiation codon (see Figure 3) . A comparison of the pCRII/3 cDNA sequence with the Pl.GALN-A genomic sequence established that exon 1 of the human GalNAc-transferase gene contains 104 bp of the GalNAc-transferase 5'-untranslated sequence, in addition to the translation initiation codon and 139 bp of coding sequence. Additional non-coding GalNAc-transferase exons, 5' of exon 1, have not presently been identified.
Attempts to amplify the GalNAc-transferase 3'-untranslated sequences downstream of those previously published, using 3'-RACE procedures, produced no detectable PCR products. Therefore, the genomic DNA sequence obtained directly from Pl.GALN-B that contains exon 11 (corresponding to human GalNAc-transferase cDNA nucleotides 1534 -2154 Meurer et al, 1995) , in addition to 1282 nucleotides of 3' genomic sequence, is presented in Figure  4 . Analysis of this sequence identifies at least three potential polyadenylation consensus sequences (AATAAA), located at nucleotide positions 2128, 2682, and 2880, respectively. It is not presently known whether any of these putative signals are functional, or if there are other human GalNAc-transferase exons containing additional 3'-untranslated sequences.
Characterization of a pseudogene related to the human GalNAc-transferase gene
As stated above, preliminary sequence data indicated that the first PI clone isolated, Pl.GALN-i//, contained genomic sequences with characteristics of a human GalNAc-transferase pseudogene. Restriction site mapping of Pl.GALNip DNA demonstrated that the insert contains £coRI fragments differing from those obtained from Pl.GALN-A and Pl.GALN-B. In fact, the entire homologous GalNActransferase sequence of Pl.GALN-i// is contained within Fig. 3 . Comparison of the human GalNAc-transferase cDNA and the homologous Pl.GALN-^I' pseudogene sequences. The ~ 3.1 kb sequence region of the GalNAc-transferase pseudogene (obtained from the Pl.GALN-i/»/SK subclone) that is homologous to the human GalNAc-transferase cDNA sequence is shown above the cDNA sequence. The newly obtained 5'-end cDNA sequence is underlined. The initiation and termination codons of the cDNA are indicated by three arrowheads, and the primers used to amplify the 2.4 kb pseudogene fragment are over-and underlined. Exon junctions are labeled with bold numbers. The exon 2 sequence is represented by lowercase, italicized lettering, and inserted pseudogene sequences (1 and 2) are shown in lowercase lettering. Fig. 4 Sequence of the functional human GalNAc-transferase gene containing exon 11. The nucleotide sequence of the human GalNAc-transferase gene corresponding to exon 11, in addition to 1282 nucleotides downstream, is shown. Numbers to the left of the sequence correspond to the human GalNAc-transferase cDNA nucleotide sequence. GalNAc-transferase coding region sequences are in capital letters and the termination codon is italicized and underlined. The end of the human GalNAc-transferase cDNA sequence is indicated by an arrow. All putative polyadenylation consensus sequences are double underlined. a single 5.0 kb EcoRl fragment (subcloned to produce Pl.GALN-i/r/SK). Sequencing of the Pl.GALN-^/SK 5.0 kb fragment revealed a ~ 3.1 kb region that, overall, shares greater than 78% identity with the human GalNAc-transferase cDNA sequence. A comparison between the GalNAc-transferase cDNA and the related Pl.GALN-i/^/SK sequences, displayed in Figure 3 , clearly shows that the Pl.GALN-i/» 3.1 kb region contains multiple nucleotide changes, insertions, and deletions. These sequence alterations cause frame-shift and nonsense mutations which prematurely terminate the potential GalNAc-transferase open reading frame that follows the shared translation initiation start codon (see Figure 3) . The alignment presented in Figure 3 includes three large gaps (nucleotide 236 insertion/deletions > 100 bp) that were introduced to maximize the degree of identity between the two sequences. The first large gap was placed in the Pl.GALN-i/f 3.1 kb sequence between alignment positions 296 and 470 (175 bp), due to the deletion of a region corresponding to exon 2 of the functional GalNAc-transferase gene. The second and third large gaps were placed at alignment positions 1105 to 1699 (595 bp) and 2211 to 2486 (276 bp), respectively; both gaps were needed to account for the presence of inserted sequence elements in Pl.GALN-i/f. These inserted sequences appear unrelated to human GalNActransferase gene. First, the relative locations of the insertions in Pl.GALN-i/f (internal to sequences corresponding to GalNAc-transferase exons 6 and 10; see Figure 3 ) strongly suggest that they are not derived from partially or aberrantly spliced GalNAc-transferase transcripts. Second, a Pythia repetitive DNA element server search (Jurka et ai, 1992 ) and a GenBank (version 90) search revealed that the first insert was composed of a 371 bp repetitive element (corresponding to alignment positions 1318-1688; see Figure 3 ) that shared ~ 71% identity with the medium reiteration frequency (MER) element first identified as number 26 (Jurka et ai, 1993) , and later found to belong to the mammalian long terminal repeat (MLT)-l (Smit, 1993) . Matches with the second insert were not found in the human genome, using either of the two search programs. However, it cannot be unequivocally stated that the inserted elements are unrelated to human GalNAc-transferase gene sequences because the complete GalNActransferase intron sequences have not been determined. Thus, despite the loss of the GalNAc-transferase transcript region corresponding to exon 2 and the presence of two apparently unrelated inserts, the structure of the homologous GalNAc-transferase gene contained in Pl.GALN-</> is consistent with that of a processed pseudogene (Vanin, 1985) .
Assuming that all of the insertion/deletions occurred as single genetic events (nucleotide insertions/deletions are equal to a single mismatch regardless of length) the overall shared sequence identity between the human GalNActransferase cDNA and the 3.1 kb region of Pl.GALN-i/i/ SK is calculated to be 78.6%. The degree of divergence between these two sequences suggests that the retroviral transposition event responsible for the GalNAc-transferase pseudogene occurred early in the descent of Homo sapiens (see Discussion).
Southern blot analysis of the GalNAc-transferase gene and the homologous pseudogene
In order to further characterize the functional human GalNAc-transferase gene and its related pseudogene, a Southern blot analysis was performed. The blot, containing human genomic DNA digested with the restriction endonuclease Pstl, was first probed with a [ 32 P]-labeled cDNA fragment corresponding to human GalNAc-transferase cDNA clone nucleotides -31 to 2154 (Meurer et ai, 1995) . As shown in Figure 5 , this resulted in the identification of seven hybridization-positive bands of 7.6, 6.2, 4.8,3.7, 3.6, 2.4, and 1.7 kb, respectively. The blot was then stripped and reprobed with a 2.4 kb fragment derived from the Pl.GALN-t/f/SK clone (derived by PCR; see Materials and methods). This analysis identified a single hybridization-positive band of 6.2 kb ( Figure 5A ). These data would suggest that the 6.2 kb fragment seen on the Pstl Southern blot probed with human GalNAc-transferase cDNA corresponds to the GalNAc-transferase pseudogene.
Chromosomal localization of the human GalNActransferase pseudogene
Previously, the probing of a BamHI-digested human/rodent somatic cell hybrid panel with the human GalNActransferase cDNA (Meurer et ai, 1995) determined that the GalNAc-transferase gene is localized to chromosome 18. To determine the chromosomal location of the human GalNAc-transferase pseudogene, a Psfl-digested somatic cell human/rodent hybrid DNA panel was screened with the 2.4 kb pseudogene containing fragment (derived by PCR from clone P1.GALN-0/SK; see above). This analysis clearly identified one hybridization positive band of approximately 6.2 kb in the lanes containing male and female human genomic DNA, as well as in the chromosome 3 lane ( Figure 5B ). Hybridizing bands were not identified in any of the other chromosome-specific lanes. To verify this result, a 5a/??HI-digested human/rodent somatic cell hybrid panel was subsequently probed with the 2.4 kb human GalNAc-transferase pseudogene probe. This probe hybridized with a 15 kb band in the human genomic DNA lanes and in the chromosome 3 lane (data not shown). Interestingly, the chromosomal location of this 15 kb band on the panel probed with human GalNAc-transferase cDNA could not be determined previously, due to probe cross-hybridization with hamster DNA at this location (Meurer et ai, 1995) . These results indicate that a human GalNAc-transferase pseudogene gene resides on chromosome 3.
Discussion
This report presents the isolation and characterization of three human genomic clones that contain sequences corresponding to a functional human GalNAc-transferase gene and one clone that contains a GalNAc-transferase related pseudogene. The data obtained indicates that the human genome encodes at least two related human GalNAc-transferase genes, one which appears to be functionally active and a second which is non-functional, and appears to be a processed pseudogene.
The functional human GalNAc-transferase gene shares several characteristics with other mammalian glycosyltransferase genes characterized to date (reviewed by Joziasse, 1992) . First, the 3' portion of the coding region, the termination codon, and the characterized portion of the 3'-untranslated region are encoded on a single exon. Second, the 5'-untranslated region of the gene is located on at least one exon. Lastly, the organization of the GalNActransferase gene is similar to one group of glycosyltransferase genes (group I), including the ABO blood group glycosyltransferases (Bennett et ai, 1995; Yamamoto et ai, 1995) , the al,3-and /31,4-galactosyltransferases (Hollis et a/., 1989 , Mengle-Gaweffl/., 1991 Joziasseefa/., 1992) , and the «2,3-(SiaT-4a) and a2,6-sialyltransferases (Svensson et ai, 1990; Wang et ai, 1993; Chang et ai, 1995) , in that its coding sequence is dispersed over multiple exons. Conversely, the coding regions of the second group of glycosyltransferase genes (group II), including the ai,2-, al,3-, and al,3(al,4)-fucosyltransferases (Kleene and Berger, 1993 , and the references therein; Rouquier et ai, 1995) , as well as the I, II, III, and core 2 GlcNAc-transferases (Pownall et ai, 1992; Ihara et ai, 1993; Bierhuizen et ai, 1995; Tan et ai, 1995) , are contained on a single exon. However, in contrast to the group I glycosyltransferase genes, the functional human GalNAc-transferase gene described in this report does not contain an exon which encodes a large portion (over 200 amino acids) of the coding region, believed to correspond to the catalytic domain (Joziasse, 1992) . The exons of the GalNAc-transferase gene, rather, encode between 33 and 69 amino acids, with an average of 51 amino acid residues per exon. Thus, the organization of the functional human GalNAc-transferase gene is unique among the other group I glycosyltransferase genes in this respect.
In addition to the functional gene, the human genome was found to contain at least one homologous GalNActransferase gene corresponding to a processed pseudogene. Analysis of this pseudogene sequence revealed several interesting features, common to many previously characterized processed pseudogenes (reviewed by Vanin, 1985) . The existence of multiple nucleotide changes and insertion/ deletion events in the putative coding region clearly indicate that this gene is not functional. The pseudogene contains an insignificantly sized open reading frame, as it is capable of only encoding a 58 amino acid polypeptide. Although the pseudogene contains two large nucleotide insertions in the putative coding region (595 and 276 bp, respectively) and has a deleted segment which corresponds almost exactly to exon 2 of the active human GalNActransferase gene, the GalNAc-transferase pseudogene has retained significant sequence identity (78.6%) with the human GalNAc-transferase transcript coding region. Furthermore, the corresponding 5'-and 3'-untranslated regions of the GalNAc-transferase transcript and the pseudogene share a similar degree of identity (~ 75%), consistent with the entire pseudogene sequence having evolved at the same rate, the rate expected for 'neutral' non-coding DNA (Hayashida and Miyata, 1983) . Lastly, the chromosomal locations of the human GalNAc-transferase pseudogene and the corresponding functional gene are not syntenic, in that the pseudogene is localized to chromosome 3 and the functional gene to chromosome 18 (Meurer et al., 1995) .
The degree of divergence between the functional GalNAc-transferase gene and the pseudogene (21.4%) suggests that the retrovirus transposition event responsible for placing the pseudogene within chromosome 3 occurred early in the descent of man. (The percent divergence values quoted in this manuscript have not been corrected for superimposed mutations [Jukes and Cantor, 1969] , and we have consistently used uncorrected divergence values from the referenced resources in the analyses presented.) A reasonable determination of when this event occurred can be estimated from the divergence data. To do this, an estimate for the time of separation of the pseudogene from the functional GalNAc-transferase gene can be obtained using either its rate of evolutionary divergence or a comparison with divergence tables derived from the analysis of an orthologously related gene(s) in a series of extant species representing a large evolutionary time. For the present case, due to the relatively large degree of diver-gence between the functional GalNAc-transferase gene and the pseudogene (21.4%), the best estimate is obtained from the divergence tables presented by Koop et al. (1989) and Bailey etal (1991) . These tables show a 12-15% divergence for non-coding DNAs of species that last shared a common ancestor at the time of the platyrrhine-catarrhine split (New World monkeys from Old World monkeys, apes, and human lineages), which occurred about 35 million years ago (MYA). Additionally, a 23-28% divergence is seen for similar DNAs of species that last shared a common ancestor at the time of the splits between tarsier and anthropoid, and haplorhines (tarsier/anthropoids) and strepsirhines (lemur/galago), at about 50 and 60 MY A, respectively. Because the degree of divergence between the two related GalNAc-transferase genes is closer to that found for species that separated about the time of the tarsier and anthropoid split, we suggest that the retroviral transposition event that placed a copy of the GalNAc-transferase transcript onto chromosome 3 occurred nearly 45 MYA.
In summary, the data presented in this report characterize the structure and organization of a functional human GalNAc-transferase gene, as well as that of a homologous, processed pseudogene. Comparisons of the two related gene sequences and their chromosomal localizations indicate that they are from distinctly different genetic loci and diverged approximately 45 million years ago.
Materials and methods Materials
DNA restriction enzymes and DNA modification enzymes were purchased from Gibco/BRL Life Technologies. [a- P]ATP (3000 Ci/mmol) were obtained from Amersham. Synthetic oligonucleotide primers were prepared by Genosys Biotech., Inc. PCR was performed using the GeneAmp PCR System 2400 (Perkin Elmer). The Sequenase kit (#70140) from US Biochemicals, Inc. was used for all dideoxy sequencing of plasmid subclones, and the Perkin Elmer Amplicycle sequencing kit was used for direct cycle sequencing of A and PI clones.
Isolation and characterization of X.FIX human placenta genomic clones
A human placenta genomic DNA library, constructed in AFIX™II (Stratagene, no. 946203), was screened by plaque hybridization with a [ 32 P]-labeled, PCR-generated 5'-end human GalNAc-transferase cDNA fragment (corresponding to bp 1-263; see Meurer etal, 1995) . Approximately 1 x 10 6 recombinant clones were screened which resulted in the identification of a single hybridization-positive bacteriophage clone, A.HG-5. A.HG-5 was plaque-purified and its DNA isolated using the bacteriophage and DNA purification methods outlined by Sambrook et al (1989) . The resulting phage DNA was characterized by restriction digestion and Southern blot analysis. Hybridization-positive EcoRI and Hindlll restriction fragments, identified using the [ 32 P]-labeled probe described above, were each subcloned into the sequencing vector Bluescript SK (Stratagene). Direct sequencing of these subcloned A.HG-5 DNA restriction fragments was performed (see Materials), in both directions, using oligonucleotide primers derived from the 5' end of the human GalNAc-transferase cDNA coding region.
Isolation and characterization of human genomic PI clones
A human genomic bacteriophage PI library was screened (Genome Systems, Inc., St. Louis, MO) for clones containing the GalNAc-transferase gene, on three separate occasions, using human GalNAc-transferase genespecific PCR amplicon primers. For the first screening, one set of opposing PCR probe primers was designed (primers A' and B'; see Figure 1A ), corresponding to human GalNAc-transferase cDNA nucleotide positions 1476-1494 (sense primer A'; 5'-TACAATGCTCAAATGCCAC-3') and positions 1686-1666 (antisense primer B'; 5'-TTGGTCTCAGAATAT-TTCTGG-3'), respectively (Meurer et al, 1995) . This screening resulted in the isolation of a single PI clone, subsequently named Pl.GALN-i// (Genome Systems clone #420). This clone was colony purified, its DNA isolated and transferred to Cre-bacterial strain DH10B by Genome Systems, Inc. Any additional isolations of Pl.GALN-i/< DNA were performed by Genome Systems. Inc. (as well as for all of the other PI clone DNAs described below). Pl.GALN-i/< DNA was analyzed by restriction mapping and Southern blot analysis, which revealed a single, hybridization-positive 5.0 kb £coRI restriction fragment that was subcloned into the EcoRI site of the Bluescript SK sequencing vector (Stratagene). The 5.0 kb DNA insert of the resulting plasmid, Pl.GALN-i/</SK, was subjected to sequencing using the dideoxy chain termination method of Sanger et al (1977) .
The second PI screening was performed using genomic sequence information from clone A.HG-5, in order to avoid the isolation of clones containing pseudogene sequences. The opposing set of PCR amplicon primers consisted of a sense primer C (5'-CCACTATAGAGAGATT-CAG-3'), corresponding to GalNAc-transferase intron 1 sequence obtained from clone A.HG-5 (see Figure IB) , and an antisense primer D' (5'-CCAGGACCTTCATGAGGCTTTTG-3'), corresponding to nucleotide positions 176-154 of the human GalNAc-transferase cDNA (Meurer et al, 1995) . This resulted in the isolation of one clone (Genome Systems clone #4793) referred to as Pl.GALN-A. This clone was colony purified, and its DNA was isolated and subsequently analyzed by restriction mapping and Southern blotting. Direct sequencing, using the cycle sequencing method (see Materials), was performed to characterize the GalNActransferase gene exons and intron/exon boundaries contained within Pl.GALN-A.
The insert of Pl.GALN-A did not contain the 3'-end of the human GalNAc-transferase gene (specifically, sequences 3' of human GalNActransferase cDNA nucleotide 1299). Thus, using the sequence information from Pl.GALN-A, a third human PI library 'walk' screening was performed using two sets of opposing PCR amplicon primers. The first set of primers (set 1: sense primer E'; 5'-CTCCTCTGCAGGATGTAAGGy and antisense primer F'; 5'-GACAGCACGTTCAGCAGAAAC-TAC-3') amplified nucleotides 1781 to 2054 of the 3'-untranslated region of the human GalNAc-transferase cDNA (see Figure 1C) . The second set of amplicon primers (se(2:sense primer G'; 5'-GGCAGTGTGGAG-GAACTTTGGAAATTG-3' and antisense primer H'; 5'-GCACATCT-GTAAAACCTGGGCTAGCAACAC-3') were derived from the 3'-end of clone Pl.GALN-A (see Figure 1C) , and amplified a -420 bp exon/ intron region corresponding to exon/intron 8. One positive PI clone, referred to as Pl.GALN-B (Genome Systems #5656), was isolated and its DNA purified and analyzed as outlined above for clone Pl.GALN-A.
Determination of GalNAc-transferase intron/exon boundaries and intron sizes
Human GalNAc-transferase exon regions encoded by the Pl.GALN-A, -B, and -ifi/SK clones were determined by bi-directional sequencing, using oligonucleotide primers corresponding to sequences of the published human GalNAc-transferase cDNA (Meurer et al, 1995) . To define the lengths of the corresponding intron regions, long-range PCR was performed on the respective PI clone templates, using sets of opposing exonspecific PCR primers corresponding to sequences from adjacent exons. PCR was performed using the GeneAmp XL PCR kit (Perkin Elmer), following the manufacturer's protocol entitled 'Amplification of a A Control Template using the GeneAmp PCR System 9400'. The amplified products were analyzed by gel electrophoresis on a 1% agarose gel.
Isolation of 5'-end cDNA sequences by 5'-RACE PCR
A portion of the 5'-untranslated region of the human GalNAc-transferase cDNA was isolated from human salivary gland cDNA using the Ampli-FINDER 5'-RACE kit (Clontech) essentially as previously described by Meurer et al. (1995) . The following modifications to this procedure were used: PCR amplification was performed using the anchor sense primer (supplied in kit) and a human GalNAc-transferase antisense primer (5'-CTTGCAGTATGCAAA 1IT1CT-3'; corresponding to nucleotide positions 24-4 of the human GalNAc-transferase cDN A). Amplified products were ligated into the TA cloning vector pCR-II (Invitrogen). Resulting colonies were screened by hybridization using a [ 32 P]-labeled 101 bp human GalNAc-transferase cDNA PCR fragment corresponding to nucleotides -31 to 70. Plasmid DNAs from five hybridization-positive clones, pCRII/1 to pCRH/5, were purified and subsequently sequenced as previously described (Meurer et al, 1995) .
Southern blot analysis of human genomic DNA
A human genomic DNA Southern GENO-BLOT was purchased from Clontech Labs., Inc. (#7700-1). The blot was prehybridized using ExpressHyb hybridization solution (Clontech), as outlined by the manufacturer, and subsequently hybridized overnight at 65°C with fresh ExpressHyb solution containing a [ 32 P]-labeled probe corresponding to nucleotide positions -31 to 2154 of the human GalNAc-transferase cDNA (Meurer etai, 1995) . Following hybridization, the blot was washed two limes at room temperature (20 min each) with 2 X SSC/0.05% SDS. A third wash was performed at 65°C with 0.1 x SSC/0.1% SDS for 45 min, after which the blot was subjected to autoradiography. The blot was stripped according to the manufacturer's protocol, prehybridized as outlined above, and re-probed overnight at 65°C with a PCR-generated, Pl.GALN-i/< 2.4 kb pseudogene fragment. This fragment was amplified using primers A and B and the corresponding PCR procedure described by Meurer etai, (1995) , with Pl.GALN-i///SK as the template (see Figure  3 for primer location). The blot was washed as described above and hybridization-positive bands were visualized by autoradiography.
Chromosomal localization of the human GalNActransferase pseudogene
A Pst\-digested human/rodent Somatic Cell Hybrid panel was obtained from Oncor Co. and probed with the purified. PCR-generated. [ 32 P]-labeled 2.4 kb GalNAc-transferase pseudogene fragment (see above), essentially as outlined by the manufacturer. Briefly, the panel was prehybridized (50°C) and then hybridized overnight at 50°C with the radiolabeled probe. The blot was subsequently washed at room temperature, three times, with 0.1 x SSC/0.1% SDS. A high-stringency wash was performed at 62°C for 1 h with 0.1 X SSC/0.1% SDS. The hybridizationpositive bands which resulted were visualized by autoradiography.
